Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for patients with genetically-defined cancers, based on breakthroughs in the field of epigenetics, today announced its participation in six upcoming conferences.
- Pharmaceutical Strategic Outlook Conference at the Grand Hyatt New York in New York City, NY on Thursday, April 12th, at 12:00 Noon
- University of Chicago’s Molecular and Translational Breakthroughs in Leukemia Research Conference at the University of Chicago in Chicago, IL on Friday, April 13th, beginning at 8:30 AM
- Business Development Biotech Conference at the Mandarin Oriental Boston hotel in Boston, MA on Tuesday, April 17th, at 4:00 PM
- BioCentury’s 19th Annual Future Leaders Conference the Millennium Broadway Hotel & Conference Center in New York City, NY on Friday, April 20th, at 2:00 PM
- 36th Annual UNC Lineberger Scientific Symposium at the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, NC, on Thursday, April 26th, at 9:45 AM
- Deloitte Recap’s Allicense 2012 Conference at the Palace Hotel in San Francisco, CA, on Tuesday, May 1st, at 2:30 PM
About Epizyme
Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of personalized therapeutics for patients with genetically-defined cancers, based on breakthroughs in the field of epigenetics. Genetic alterations in the HMTs are strongly associated with the underlying causes of multiple human diseases, including cancer. Epizyme’s patient-driven approach represents the future of personalized therapeutics by creating better medicines for the right patients more quickly and at lower cost than traditional approaches. Epizyme has benchmark partnerships with GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS). www.epizyme.com
Contacts:
Kari Watson or Jennifer
Conrad, 781-235-3060
